We are live on ! Find out more
ACXP icon

Acurx Pharmaceuticals

9 hedge funds and large institutions have $1.15M invested in Acurx Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more capital invested

Capital invested by funds: $455K → $1.15M (+$690K)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.12% more ownership

Funds ownership: 0.05%0.17% (+0.12%)

10% less funds holding

Funds holding: 109 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.14%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
1
Closed
4
Calls
Puts
Net Calls
Net Calls Change

ACXP Hedge Fund Activity: Q1 2022 in Review

9 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q1 2022, worth a combined $1.15M — up 152% from $455K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ACXP and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.

The largest buyer was Draper Asset Management, opening a new position worth an estimated $1.04M. The largest seller was HRT Financial, exiting entirely with an estimated $62K sold.

  • 9 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q1 2022, down from 10 in Q4 2021.
  • Funds reported $1.15M of Acurx Pharmaceuticals stock for Q1 2022, up 152% quarter-over-quarter.
  • 3 funds opened new Acurx Pharmaceuticals positions in Q1 2022 and 4 closed out, a net change of -1 holder.
  • The largest Acurx Pharmaceuticals buyer in Q1 2022 was Draper Asset Management, an estimated $1.04M added.
  • The largest Acurx Pharmaceuticals seller in Q1 2022 was HRT Financial, an estimated $62K sold.

Based on aggregated 13F filings for Q1 2022.